News & Updates

Treatment with tenofovir alafenamide (TAF) is generally safe and effective for the prevention of hepatitis B virus (HBV) mother-to-child transmission (MTCT), reports a study, noting that the expected 8-week prenatal duration is feasible.

In the final overall survival (OS) analysis of the phase III MIRASOL trial, the survival benefit previously reported with the antibody drug conjugate mirvetuximab soravtansine (MIRV) remains superior to investigator’s choice chemotherapy (ICC) for the treatment of folate receptor alpha-positive, platinum-resistant ovarian cancer (FRα+ PROC).

Reducing systolic blood pressure (SBP) to a target of less than 140 mm Hg does not appear to have any negative effects on diffusion-weighted imaging lesion frequency and volume in patients with acute intracerebral haemorrhage (ICH), as shown in ICHADAPT-2*.

New research presented at EHRA 2025 has shown that patients who have taken antidepressants for extended periods are at increased risk of sudden cardiac death.

Semaglutide may also confer hepatoprotective benefits, with interim efficacy data from the ongoing phase III ESSENCE study showing that the glucagon-like peptide-1 (GLP-1) receptor agonist helps dial down disease activity in patients with metabolic dysfunction–associated steatohepatitis (MASH) and moderate-to-severe fibrosis.

Greater intrinsic motivation for engaging in healthy lifestyle behaviours appears to promote long-term postpartum weight reduction and may be a promising target for interventions, suggests a study.

Gynaecologic oncology patients with better sleep efficiency in the days before a surgical procedure are more likely to have fewer postoperative complications and require lower doses of opioid pain medication upon hospital discharge, according to a study.

For hospitalized individuals initiating treatment for alcohol use disorder (AUD), oral naltrexone is equally efficacious as the extended-release injectable formulation in terms of reducing heavy drinking days, as shown in a study.

In adult patients with treatment-naive neovascular age-related macular degeneration (nAMD), the use of faricimab shows superior anatomic outcome compared with aflibercept during the head-to-head dosing phase, reports a study.